| 血清中microRNA-127对鼻咽癌患者化疗抗性的预测价值 |
| |
| 引用本文： | 阮鹏,谭爱丽.血清中microRNA-127对鼻咽癌患者化疗抗性的预测价值[J].实用肿瘤学杂志,2019,33(6):508-512. |
| |
| 作者姓名： | 阮鹏 谭爱丽 |
| |
| 作者单位： | 1.武汉大学人民医院肿瘤科(武汉 430060); 2.武汉大学人民医院妇产科 |
| |
| 基金项目： | 国家自然科学基金青年基金(编号:81801421) |
| |
| 摘 要： | 目的 探讨血清微小RNA(micro RNA)在预测鼻咽癌患者化疗有效性方面的临床价值。方法 纳入2010年1月—2016年12月我院收治的187例接受顺铂联合化疗的鼻咽癌患者,其中化疗敏感患者123例,化疗抵抗患者64例。检测所有初次化疗前血清中miRNA的表达水平,并以健康体检人群为对照,评估血清miRNA与鼻咽癌患者化疗有效性的关系及其预测价值。结果 鼻咽癌患者血清miR-127水平显著高于健康对照组(4.3±1.6 vs. 1.4±0.5)(P＜0.001),化疗抵抗患者的血清miR-127水平显著高于化疗敏感患者(4.5±1.3 vs. 3.8±1.7)(P＜0.001)。ROC曲线显示血清miR-127对鼻咽癌患者化疗抵抗的预测价值较好(AUC=0.702,P＜0.001),最佳阈值为4.2,灵敏度82.3%,特异度76.3%。与化疗敏感组相比,化疗抵抗组患者的T3-4期、N3期和TNM Ⅲ~Ⅳ期患者比例均明显升高(P＜0.01),且miR-127≥4.2的比例也升高(P＜0.001)。多因素Logistics回归分析显示TNM分期(OR=1.655,95% CI:1.142~2.584,P=0.016)和血清miR-127≥4.2(OR=2.231,95% CI:1.762~4.503,P=0.001)是影响鼻咽癌患者化疗抵抗的独立危险因素。结论 血清miR-127水平的升高可能是预测鼻咽癌患者化疗抵抗的重要危险因素。
|
| 关 键 词： | 鼻咽癌 化疗抵抗 微小RNA |
| 收稿时间： | 2019-04-19 |
Predictive value of serum microRNA-127 for chemotherapy resistance in patients with nasopharyngeal carcinoma |
| |
| RUAN Peng,TAN Aili.Predictive value of serum microRNA-127 for chemotherapy resistance in patients with nasopharyngeal carcinoma[J].Journal of Practical Oncology,2019,33(6):508-512. |
| |
| Authors: | RUAN Peng TAN Aili |
| |
| Affiliation: | 1.Department of Oncology,Renmin Hospital of Wuhan University,Wuhan 430060,China; 2.Department of Obstetrics & Gynecology,Renmin Hospital of Wuhan University |
| |
| Abstract: | Objective The objective of this study was to investigate the clinical value of serum microRNA in predicting chemotherapy efficacy in patients with nasopharyngeal carcinoma.Methods A total of 187 patients with nasopharyngeal carcinoma who received cisplatin combined chemotherapy were enrolled in our hospital from January 2010 to December 2016,including 123 patients with chemotherapy sensitivity and 64 patients with chemotherapy resistance.The serum levels of miRNA before the initial chemotherapy were measured,the efficacy and predictive value of serum miRNA in nasopharyngeal carcinoma patients were evaluated using healthy subjects as controls.Results Serum level of miR-127 in nasopharyngeal carcinoma patients was significantly higher than that in healthy controls(4.3±1.6 vs. 1.4±0.5,P＜0.001).Serum level of miR-127 was significantly higher in chemotherapy-resistant patients than that in chemotherapy-sensitive patients(4.5±1.3 vs. 3.8±1.7,P＜0.001).The ROC curve showed that the predictive value of serum miR-127 for chemotherapy resistance in nasopharyngeal carcinoma patients was 0.702(P＜0.001),with the optimal cut-off value of 4.2,sensitivity of 82.3% and specificity of 76.3%.Compared with the chemotherapy-sensitive group,the proportion of patients with T3-4,N3 and TNM Ⅲ~Ⅳ in the chemotherapy-resistant group was significantly increased(P＜0.01),and the proportion of miR-127≥4.2 was also increased(P＜0.001).Multivariate logistic regression analysis showed that TNM staging(OR=1.655,95% CI:1.142~2.584,P=0.016)and serum miR-127≥4.2(OR=2.231,95% CI:1.762~4.503,P=0.001)were independent risk factors affecting chemotherapy resistance in nasopharyngeal carcinoma patients.Conclusion The elevated serum level of miR-127 is an important risk factor for predicting chemotherapy resistance in patients with nasopharyngeal carcinoma. |
| |
| Keywords: | Nasopharyngeal carcinoma Chemotherapy resistance microRNA |
|
| 点击此处可从《实用肿瘤学杂志》浏览原始摘要信息 |
|
点击此处可从《实用肿瘤学杂志》下载全文 |
|
